Bupropion Can Be Used Cautiously in Cardiac Patients, But Is Not First-Line
Bupropion is reasonable to use with caution in patients with established cardiovascular disease, but requires careful monitoring of heart rate and blood pressure, and is not the preferred smoking cessation medication in this population. 1
Context and Evidence Quality
The most relevant guidance comes from the 2016 AACE/ACE obesity guidelines, which directly address bupropion use in cardiac patients. While these guidelines focus on naltrexone/bupropion ER for weight loss rather than bupropion alone for smoking cessation, the cardiovascular safety considerations are directly applicable.
Key Recommendations by Clinical Scenario
For Established Cardiovascular Disease
Preferred alternatives exist: In patients with established atherosclerotic cardiovascular disease, orlistat and lorcaserin are the preferred medications. However, naltrexone ER/bupropion ER (and by extension, bupropion) is "reasonable to use with caution" if weight-loss goals are met, with careful monitoring of heart rate and blood pressure 1. This Grade A recommendation (BEL 1) indicates strong evidence supporting cautious use rather than absolute avoidance.
For Smoking Cessation in Cardiac Patients
The 2012 European cardiovascular prevention guidelines note that bupropion "aids long-term smoking cessation with similar efficacy to NRT" and has been tested in patients with coronary heart disease 2. The 2025 Canadian cardiovascular guidelines specifically state that "although bupropion is effective in generalized outpatient populations, results have been less convincing among patients with ACS" 3.
Critical Safety Considerations
Blood Pressure Monitoring is Essential
The FDA label explicitly warns about hypertension risk 4:
- In clinical trials, bupropion caused statistically significant increases in systolic blood pressure (mean 1.3 mmHg increase)
- 2% of patients developed hypertension requiring discontinuation
- In patients with stable congestive heart failure, bupropion caused exacerbation of pre-existing hypertension in 2 subjects, leading to treatment discontinuation
Contraindications in Hypertension
Naltrexone ER/bupropion ER is contraindicated in uncontrolled hypertension and should be avoided if other medications can be used because it cannot be expected to reduce blood pressure 1.
Lack of Data in Acute/Unstable Disease
Critical gap: The FDA label explicitly states "There are no controlled studies assessing the safety of bupropion in patients with a recent history of myocardial infarction or unstable cardiac disease" 4.
Research Evidence on Efficacy and Safety
Mixed Results in Post-MI Patients
The research evidence shows inconsistent benefits:
A 2013 RCT of 392 post-AMI patients found bupropion was well-tolerated and safe but not effective for smoking cessation (37.2% vs 32.0% abstinence at 12 months, p=0.33). Major adverse cardiac event rates were similar (13.0% vs 11.0%) 5
A 2013 meta-analysis of 3 RCTs (773 patients, predominantly ACS) found bupropion improved abstinence at end of treatment but this effect did not persist at 12 months. Safety data were inconclusive 6
A 2003 European study of 629 CVD patients showed bupropion doubled quit rates at 1 year (22% vs 9%, p<0.001) with no clinically significant changes in blood pressure or heart rate 7
A 2006 US study of 248 hospitalized ACS patients showed short-term benefit (37.1% vs 26.8% at 3 months, adjusted OR 1.91) but no long-term benefit, with no difference in cardiovascular events 8
Cardiovascular Safety Meta-Analysis
A 2021 meta-analysis of 12 RCTs (19,176 patients, 7,354 patient-years) found no association between bupropion and major adverse cardiovascular events (OR 0.90,95% CI 0.65-1.25, p=0.52) 9. This provides reassurance about overall cardiovascular safety in selected patients.
Practical Algorithm for Use
Step 1: Assess cardiac stability
- Recent MI (<2 weeks) or unstable cardiac disease → Avoid bupropion (no safety data)
- Stable cardiovascular disease → Proceed to Step 2
Step 2: Evaluate blood pressure control
- Uncontrolled hypertension → Contraindicated
- Controlled hypertension or normotensive → Proceed to Step 3
Step 3: Consider alternatives first
- For smoking cessation: Varenicline or NRT are preferred 3
- For weight loss with CVD: Orlistat or lorcaserin are preferred 1
Step 4: If bupropion is chosen
- Monitor blood pressure and heart rate at baseline, weekly during titration, then regularly
- Start at lower dose (150 mg once daily) and titrate slowly
- Discontinue if blood pressure becomes uncontrolled or heart rate significantly increases
Common Pitfalls to Avoid
- Don't assume bupropion is contraindicated in all cardiac patients - it's not, but requires careful selection and monitoring
- Don't use in acute/unstable cardiac disease - wait until patient is stabilized
- Don't forget to monitor blood pressure - this is the primary cardiac safety concern
- Don't expect robust long-term smoking cessation efficacy in post-ACS patients - the evidence shows limited benefit beyond short-term
Bottom Line
Bupropion is not absolutely contraindicated in cardiac patients, but it's a second-line option requiring careful patient selection (stable disease, controlled blood pressure) and vigilant monitoring. The benefits of smoking cessation far outweigh theoretical risks in appropriately selected patients, but alternative agents (varenicline, NRT) should be considered first in the cardiovascular population.